Plavix News and Research

RSS

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

During a meeting with the investment community today, Bristol-Myers Squibb Company will provide a comprehensive business overview, highlight positive pipeline developments and provide 2013 minimum non-GAAP earnings per share guidance.

5 Mar 2010

FDA warns about drug mix-ups; drug maker agrees to name change to avoid confusion

The U.S. Food and Drug Administration today warned consumers about the potential for serious side effects from mistakenly using Maalox Total Relief instead of other Maalox products. The two products are intended for the relief of different symptoms and contain different active ingredients.

18 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated with concomitant use of clopidogrel and PPIs.

10 Feb 2010

Emerging Healthcare Solutions issues Term Sheet review to ThromboVision

Emerging Healthcare Solutions, Inc. announced today that management has formally delivered an actionable Term Sheet to ThromboVision for review and that follow up communications have been very favorable.

9 Feb 2010

Emerging Healthcare Solutions completes due diligence and review requirements with ThromboVision

Emerging Healthcare Solutions, Inc. announced today that the company has successfully completed the due diligence and review requirements under their recent option agreement with ThromboVision, a company that has licensed the patent on the new T-Guide® Platelet Function Analyzer, which is currently going through regulatory clearance review.

4 Feb 2010

Emerging Healthcare Solutions and ThromboVision complete due diligence process under new option agreement

Emerging Healthcare Solutions, Inc. and ThromboVision have completed phase one of their due diligence process under their new option agreement.

21 Jan 2010

Emerging Healthcare Solutions seeks business opportunities with new, patented T-Guide Platelet Function Analyzer

Emerging Healthcare Solutions, Inc. under their exclusive option agreement with Thrombovision, has begun due diligence to aggressively seek the establishment of business opportunities with the new patented T-Guide Platelet Function Analyzer.

8 Jan 2010

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

Results from a health economic substudy of the TRITON-TIMI 38 clinical trial showed that among patients with acute coronary syndromes (ACS) managed with percutaneous coronary intervention (PCI), including stenting, treatment with Effient(®) (prasugrel) compared with branded clopidogrel (Plavix(®)) was more cost effective, and in most cases cost saving.

6 Jan 2010

Emerging Healthcare Solutions to execute option agreement with ThromboVision

Emerging Healthcare Solutions, Inc. is pleased to announce the execution of an exclusive option agreement with ThromboVision, Inc. ThromboVision, a Houston-based healthcare diagnostics company committed to enabling people to lead longer and healthier lives, has developed and patented T-Guide®, a new cutting-edge diagnostic test to assist medical professionals with the treatment of heart disease.

29 Dec 2009

PGxHealth, DHZ announce collaboration in genetic variant study with response to clopidogrel

PGxHealth, a division of Clinical Data, Inc., today announced that it has established a research collaboration with Deutsches Herzzentrum (DHZ), Munich, Germany, to evaluate the predictive value of genetic markers, including PGxHealth proprietary markers, for response to clopidogrel (Plavix®).

22 Dec 2009

Generic erosion of premium-priced branded agents to offset sales of new agents

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of premium-priced branded agents will offset sales of new agents and will cause the acute coronary syndrome market for drugs in the hospital setting to decrease from $800 million in 2008 to $729 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

8 Dec 2009

Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel

Results from a new study showed patients with type 2 diabetes who also had coronary artery disease (CAD) experienced greater antiplatelet activity with the investigational antiplatelet drug prasugrel compared to Plavix(R) (clopidogrel). Patients who received a 60 mg loading dose and 10 mg maintenance dose of prasugrel achieved significantly greater platelet inhibition compared with a 600 mg loading dose and 150 mg maintenance dose of Plavix.

4 Dec 2009

Health companies' momentum may cut right through reform savings

Health companies have done better than the rest of corporate America during the past decade, MarketWatch/Seattle Times reports. While profits at the S&P 500 companies declined slightly over 10 years, "[d]ata compiled by MarketWatch show that the 52 health-care companies in the index are about to close out the decade with average profits that nearly tripled."

25 Nov 2009

DTCA linked with increased Medicaid pharmacy expenditures

Direct-to-consumer advertising (DTCA) for a commonly prescribed antiplatelet drug does not appear associated with increased use, but may be associated with increased drug costs and Medicaid pharmacy expenditures, according to a report in the November 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

24 Nov 2009

New Drug Application for ticagrelor submitted to the FDA

AstraZeneca today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS).

23 Nov 2009

VerifyNow System, a rapid platelet function assessment platform, evaluated at AHA's Scientific Sessions

Accumetrics, Inc., developer of the VerifyNow System, the first point-of-care method for measuring platelet reactivity, announces that its market-leading VerifyNow P2Y12 Test was one of multiple methods evaluated in the POPular study, which was presented during a Late Breaking Clinical Trials session at the American Heart Association's annual Scientific Sessions.

20 Nov 2009

FDA: Plavix-Prilosec combination may reduce anti-clotting effect

Patients should avoid using the stomach acid reducer Prilosec/Prilosec OTC (omeprazole) with the anti-clotting drug Plavix (clopidogrel), the U.S. Food and Drug Administration warned on Nov. 17.

19 Nov 2009

Betterthanmedicare.com helps plug the "donut hole", offers discounts on drugs

With his proposed health care reform plan, President Barack Obama has set his sights on cutting name-brand prescription drug costs by 50 percent for Medicare patients who fall into the "Part D" coverage gap, universally known as the "donut hole." Plan advocates rave about the potential cost-cutting and feel it's a promising start to health care reform.

7 Nov 2009

sanofi-aventis reports financial results for the third quarter of 2009

In the third quarter of 2009, sanofi-aventis generated net sales of euro 7,400 million, up 8.0% on a reported basis. Exchange rate movements had a favorable effect of 2.0 percentage points, with the appreciation of the U.S. dollar (and to a lesser extent the yen) against the euro more than offsetting the unfavorable effects of some other currencies.

30 Oct 2009